Chemotherapy for advanced bladder carcinoma: new molecules and regimens.
Abi-Aad
A S
AS
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D005708:Gallium / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D017239:Paclitaxel / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D003841:Deoxycytidine; D014747:Vinblastine; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D005708:Gallium; D017239:Paclitaxel; D002945:Cisplatin; C027235:gallium nitrate; D002166:Camptothecin; D008727:Methotrexate; D000093542:Gemcitabine